Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Human-like collagen peptide** is a recombinant biomaterial developed by **JNU Biopharmaceutical Group** (also known as 暨大生物). It is produced using genetic engineering techniques, typically through microbial fermentation in hosts such as *E. coli* or yeast, to express peptide sequences that mimic the structural and biological properties of human collagen. Unlike animal-derived collagen, this recombinant peptide is designed to minimize immunogenicity and the risk of pathogen transmission while maintaining high biocompatibility. It functions as a bioactive scaffold and signaling molecule, interacting with cell-surface receptors like integrins to promote fibroblast adhesion, migration, and proliferation. Its primary applications include wound healing, skin repair, and medical aesthetics, where it facilitates the regeneration of the extracellular matrix and accelerates tissue recovery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human-like collagen peptide.